Literature DB >> 28749246

Identification of more potent imipridones, a new class of anti-cancer agents.

Andrew S Chi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28749246      PMCID： PMC5587098          DOI： 10.1080/15384101.2017.1355171

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Authors:  Mark N Stein; Joseph R Bertino; Howard L Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Bruce G Haffty; Robert S DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S El-Deiry; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Janice M Mehnert
Journal:  Clin Cancer Res       Date:  2017-03-22       Impact factor: 12.531

2.  Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL.

Authors:  Nicholas T Jacob; Jonathan W Lockner; Vladimir V Kravchenko; Kim D Janda
Journal:  Angew Chem Int Ed Engl       Date:  2014-05-18       Impact factor: 15.336

3.  Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Authors:  Jessica Wagner; Christina Leah Kline; Marie D Ralff; Avital Lev; Amriti Lulla; Lanlan Zhou; Gary L Olson; Bhaskara Rao Nallaganchu; Cyril H Benes; Joshua E Allen; Varun V Prabhu; Martin Stogniew; Wolfgang Oster; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2017-05-10       Impact factor: 4.534

4.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

5.  Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells.

Authors:  Sonam Dolma; Hayden J Selvadurai; Xiaoyang Lan; Lilian Lee; Michelle Kushida; Veronique Voisin; Heather Whetstone; Milly So; Tzvi Aviv; Nicole Park; Xueming Zhu; ChangJiang Xu; Renee Head; Katherine J Rowland; Mark Bernstein; Ian D Clarke; Gary Bader; Lea Harrington; John H Brumell; Mike Tyers; Peter B Dirks
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

Review 6.  Discovery and clinical introduction of first-in-class imipridone ONC201.

Authors:  Joshua E Allen; C Leah B Kline; Varun V Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L Kaufman; Richard S Pottorf; B Rao Nallaganchu; Gary L Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T Dicker; Mala K Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2016-11-08

7.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12
  7 in total
  1 in total

1.  Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.

Authors:  Francesca Amoroso; Kimberley Glass; Reema Singh; Francisco Liberal; Rebecca E Steele; Sarah Maguire; Rohinton Tarapore; Joshua E Allen; Sandra Van Schaeybroeck; Karl T Butterworth; Kevin Prise; Joe M O'Sullivan; Suneil Jain; David J Waugh; Ian G Mills
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.